BioWorld

April 12, 2010

View Archived Issues

Common Denominator of Cardiac, Vascular Disease

Biogen, Gilead, Others Warned About Misleading Promotions

Other News To Note

Stock Movers

Financings Roundup

Clinic Roundup

U.S. Patent Disclosures

Bench Press

Tengion Prices $30M IPO Despite Early Stage, High-Risk Programs

Tengion Inc., which priced a $30 million initial public offering on Friday, was easily the earliest-stage biotech to try its luck in the current IPO window. (BioWorld Today) Read More

FDA Rejects CTI Lymphoma Drug; Firm to Seek Compassionate Use

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...